Business
Bausch Health Announces Third-Quarter 2023 Results
Revenue of $2.24 billion, up 9% on both a Reported and Organic 1 basis Year-over-year reven...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health Announces Third-Quarter 2023 ResultsRevenue of $2.24 billion, up 9% on both a Reported and Organic1 basisYear-over-year revenue growth in all segments on both a Reported and Organic BasisGAAP Net Loss Attributable to Bausch Health Companies Inc. of $378 MillionAdjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $830 Million, up 8%Provides updated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceReceived U.S. Food and Drug Administration (\"FDA\") approval for CABTREOTM (IDP-126), the first and only FDA-approved fixed-dose, triple-combination topical treatment for acneLAVAL, QC / ACCESSWIRE / November 2, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\" or the \"Company\" or \"we\" or \"our\") today announced its third-quarter 2023 financial results and other key updates from the quarter.\"We are pleased with our solid third-quarter performance, as each of our business segments posted year-over-year revenue growth on both a reported and organic basis. We remain focused on advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth,\" said Thomas J. Appio, Chief Executive Officer, Bausch Health.Bausch Health (excl. B+L) R&D UpdateRED-C: prevention and delay of first episode of hepatic encephalopathyEnrollment of two global Phase 3 trials on track and expected to be completed in Q1 2024Amiselimod (S1P modulator): treatment of mild to moderate Ulcerative ColitisPhase 2 study completed enrollment in July 2023 and induction portion of the study is expected to be completed in Q4 2023CABTREOTM: first triple combination product for the treatment of acne vulgarisReceived FDA approval on October 20, 2023Commercial launch expected in Q1 2024New Drug Submission was submitted to Health Canada on May 30, 2023Clear + Brilliant® Touch: fractionated laser device for skin rejuvenationPlanned regulatory submissions on track for Europe, Canada, and Asia Pacific markets in 2024Next Generation Fraxel®: fractionated laser device for skin resurfacingFDA submission planned in Q1 2024 and approval is expected 1H 2024___________________________________1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the \"Non-GAAP Informa...